G. Middleton

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

T. Hickish, W. Greenhalf, P. Ghaneh, 2017, The Lancet. Oncology.

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

A. Norman, D. Cunningham, P. Ross, 2004, British Journal of Cancer.

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

P. Quirke, J. Cheadle, G. Middleton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial.

A. Norman, M. Nicolson, D. Cunningham, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

T. Hickish, A. Norman, D. Cunningham, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

S. Hitier, P. Follana, A. Zaniboni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

A. Wotherspoon, D. Cunningham, D. Ferry, 2013, The Lancet. Oncology.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

S. Gwyther, S. Richman, J. Wadsley, 2013, The Lancet. Oncology.

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

D. Smith, D. Cunningham, W. Allum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.